Cargando…
Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002738/ https://www.ncbi.nlm.nih.gov/pubmed/33803014 http://dx.doi.org/10.3390/life11030249 |
_version_ | 1783671533726597120 |
---|---|
author | Mathioudakis, Alexander G. Ghrew, Murad Ustianowski, Andrew Ahmad, Shazaad Borrow, Ray Papavasileiou, Lida Pieretta Petrakis, Dimitrios Bakerly, Nawar Diar |
author_facet | Mathioudakis, Alexander G. Ghrew, Murad Ustianowski, Andrew Ahmad, Shazaad Borrow, Ray Papavasileiou, Lida Pieretta Petrakis, Dimitrios Bakerly, Nawar Diar |
author_sort | Mathioudakis, Alexander G. |
collection | PubMed |
description | An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligible. The incidence and severity of vaccination side effects were assessed. The survey was completed by 2002 respondents of whom 26.6% had a prior COVID-19 infection. A prior COVID-19 infection was associated with an increased risk of any side effect (risk ratio 1.08, 95% confidence intervals (1.05–1.11)), fever (2.24 (1.86–2.70)), breathlessness (2.05 (1.28–3.29)), flu-like illness (1.78 (1.51–2.10)), fatigue (1.34 (1.20–1.49)) and local reactions (1.10 (1.06–1.15)). It was also associated with an increased risk of severe side effects leading to hospital care (1.56 (1.14–2.12)). While mRNA vaccines were associated with a higher incidence of any side effect (1.06 (1.01–1.11)) compared with viral vector-based vaccines, these were generally milder (p < 0.001), mostly local reactions. Importantly, mRNA vaccine recipients reported a considerably lower incidence of systemic reactions (RR < 0.6) including anaphylaxis, swelling, flu-like illness, breathlessness and fatigue and of side effects requiring hospital care (0.42 (0.31–0.58)). Our study confirms the findings of recent randomised controlled trials (RCTs) demonstrating that COVID-19 vaccines are generally safe with limited severe side effects. For the first time, our study links prior COVID-19 illness with an increased incidence of vaccination side effects and demonstrates that mRNA vaccines cause milder, less frequent systemic side effects but more local reactions. |
format | Online Article Text |
id | pubmed-8002738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80027382021-03-28 Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey Mathioudakis, Alexander G. Ghrew, Murad Ustianowski, Andrew Ahmad, Shazaad Borrow, Ray Papavasileiou, Lida Pieretta Petrakis, Dimitrios Bakerly, Nawar Diar Life (Basel) Brief Report An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligible. The incidence and severity of vaccination side effects were assessed. The survey was completed by 2002 respondents of whom 26.6% had a prior COVID-19 infection. A prior COVID-19 infection was associated with an increased risk of any side effect (risk ratio 1.08, 95% confidence intervals (1.05–1.11)), fever (2.24 (1.86–2.70)), breathlessness (2.05 (1.28–3.29)), flu-like illness (1.78 (1.51–2.10)), fatigue (1.34 (1.20–1.49)) and local reactions (1.10 (1.06–1.15)). It was also associated with an increased risk of severe side effects leading to hospital care (1.56 (1.14–2.12)). While mRNA vaccines were associated with a higher incidence of any side effect (1.06 (1.01–1.11)) compared with viral vector-based vaccines, these were generally milder (p < 0.001), mostly local reactions. Importantly, mRNA vaccine recipients reported a considerably lower incidence of systemic reactions (RR < 0.6) including anaphylaxis, swelling, flu-like illness, breathlessness and fatigue and of side effects requiring hospital care (0.42 (0.31–0.58)). Our study confirms the findings of recent randomised controlled trials (RCTs) demonstrating that COVID-19 vaccines are generally safe with limited severe side effects. For the first time, our study links prior COVID-19 illness with an increased incidence of vaccination side effects and demonstrates that mRNA vaccines cause milder, less frequent systemic side effects but more local reactions. MDPI 2021-03-17 /pmc/articles/PMC8002738/ /pubmed/33803014 http://dx.doi.org/10.3390/life11030249 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Brief Report Mathioudakis, Alexander G. Ghrew, Murad Ustianowski, Andrew Ahmad, Shazaad Borrow, Ray Papavasileiou, Lida Pieretta Petrakis, Dimitrios Bakerly, Nawar Diar Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey |
title | Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey |
title_full | Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey |
title_fullStr | Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey |
title_full_unstemmed | Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey |
title_short | Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey |
title_sort | self-reported real-world safety and reactogenicity of covid-19 vaccines: a vaccine recipient survey |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002738/ https://www.ncbi.nlm.nih.gov/pubmed/33803014 http://dx.doi.org/10.3390/life11030249 |
work_keys_str_mv | AT mathioudakisalexanderg selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT ghrewmurad selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT ustianowskiandrew selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT ahmadshazaad selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT borrowray selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT papavasileioulidapieretta selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT petrakisdimitrios selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey AT bakerlynawardiar selfreportedrealworldsafetyandreactogenicityofcovid19vaccinesavaccinerecipientsurvey |